BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24359969)

  • 1. Addition of in-vitro generated endothelial microparticles to von-Willebrand plasma improves primary and secondary hemostasis.
    Trummer A; Werwitzke S; Wermes C; Ganser A; Birschmann I; Budde U; Tiede A
    Thromb Res; 2014 Mar; 133(3):445-50. PubMed ID: 24359969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.
    Frontroth JP; Hepner M; Sciuccati G; Feliú Torres A; Pieroni G; Bonduel M
    Thromb Haemost; 2010 Dec; 104(6):1158-65. PubMed ID: 20941465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S; Mezzasoma AM; Leone M; Gresele P
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation.
    Jy W; Jimenez JJ; Mauro LM; Horstman LL; Cheng P; Ahn ER; Bidot CJ; Ahn YS
    J Thromb Haemost; 2005 Jun; 3(6):1301-8. PubMed ID: 15946221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin.
    Trummer A; Haarmeijer B; Werwitzke S; Wermes C; Ganser A; Budde U; Tiede A
    Haemophilia; 2013 Mar; 19(2):236-41. PubMed ID: 23051555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inborn and acquired von Willebrand disease].
    Schneppenheim R; Budde U
    Hamostaseologie; 2008 Dec; 28(5):312-9. PubMed ID: 19132162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.
    Grainick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
    J Clin Invest; 1985 Oct; 76(4):1522-9. PubMed ID: 2932469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII-mediated global hemostasis in the absence of von Willebrand factor.
    Takeyama M; Kasuda S; Sakurai Y; Shima M; Takeda T; Omura S; Naka H; Yoshioka A
    Int J Hematol; 2007 Jun; 85(5):397-402. PubMed ID: 17562614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
    Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
    Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
    Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
    Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?
    Favaloro EJ
    Semin Thromb Hemost; 2008 Feb; 34(1):113-27. PubMed ID: 18393148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies.
    Favaloro EJ
    Semin Thromb Hemost; 2006 Sep; 32(6):566-76. PubMed ID: 16977567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers.
    Weiss HJ; Meyer D; Rabinowitz R; Pietu G; Girma JP; Vicic WJ; Rogers J
    N Engl J Med; 1982 Feb; 306(6):326-33. PubMed ID: 6798442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ristocetin induced platelet aggregation in children with nephrotic syndrome].
    Taira K; Okajima C; Yamashita T; Kawahara S; Matsunaga T; Nakajima M; Kamitsuji H
    Nihon Jinzo Gakkai Shi; 1990 Jun; 32(6):659-66. PubMed ID: 2214316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agglutination of formalin-fixed, platelet-type von Willebrand's disease platelets by human von Willebrand factor.
    Takahashi H; Shibata A
    Thromb Haemost; 1984 Dec; 52(3):267-70. PubMed ID: 6241752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ristocetin in the diagnosis of von willebrand's disease: a comparison of rate and percent of aggregation with levels of the plasma factor(s) necessary for ristocetin aggregation.
    Dowling SV; Muntz RH; D'Souza S; Ekert H
    Thromb Diath Haemorrh; 1975 Nov; 34(2):465-74. PubMed ID: 1081746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges.
    Hayward CP; Moffat KA; Graf L
    Int J Lab Hematol; 2014 Jun; 36(3):334-40. PubMed ID: 24750680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
    Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
    Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low shear stress can initiate von Willebrand factor-dependent platelet aggregation in patients with type IIB and platelet-type von Willebrand disease.
    Murata M; Fukuyama M; Satoh K; Fujimura Y; Yoshioka A; Takahashi H; Handa M; Kawai Y; Watanabe K; Ikeda Y
    J Clin Invest; 1993 Sep; 92(3):1555-8. PubMed ID: 8376606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.